- Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer.
- [No author given]
- FORCE. XRAYS. 2020 Jun 1.
- News
- Free Full Text
Drug Approval: FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (U.S. Food & Drug Administration)
- Olaparib Makes OS Gains in Ovarian Cancer.
- [No authors listed]
- Cancer Discov. 2020 May 29. doi: 10.1158/2159-8290.CD-NB2020-048. Epub ahead of print.
- PMID: 32471872
- PubMed abstract
- Source abstract
- News
- Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis.
- Im SA, Xu B, Li W, Robson M, Ouyang Q, Yeh DC, Iwata H, Park YH, Sohn JH, Tseng LM, Goessl C, Wu W, Masuda N.
- Sci Rep. 2020 May 29;10(1):8753. doi: 10.1038/s41598-020-63033-4.
- PMID: 32472001
- PubMed abstract
- Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
- Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D, Nicoloso M, Scalone S, Giorda G, Baldassarre G, Sorio R, Puglisi F.
- Int J Mol Sci. 2020 May 27;21(11):E3805. doi: 10.3390/ijms21113805.
- PMID: 32471250
- PubMed abstract
- ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
- Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
- Pract Radiat Oncol. 2020 May 21:S1879-8500(20)30099-0. doi: 10.1016/j.prro.2020.04.003. Epub ahead of print.
- PMID: 32471709
- PubMed abstract
- Guideline, Review
- Free Full Text
Guideline:
Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
- PMID: 32243226
- PubMed abstract
- Source abstract